Physician profile
Caroline Lee
NPI 1124413141
$5,970.34
in general payments reported to CMS, 2019-2025
25 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $66.95 · 2021: $251 · 2022: $1,031 · 2023: $1,780 · 2024: $1,682 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,270 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,269.53 |
| Education | $198.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,524.98 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $644.49 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $473.95 | 2023-2025 | Zoryve |
| Genzyme Corporation | $387.14 | 2021-2025 | |
| Lilly USA, LLC | $334.49 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $333.82 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $320.34 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $240.41 | 2023-2025 | Adbry |
| Incyte Corporation | $236.05 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $225.15 | 2023-2024 | Vtama |
| Pfizer INC. | $206.04 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $188.22 | 2022-2024 | Ilumya |
| Amgen INC. | $167.35 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $142.47 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $116.05 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $90.70 | 2021-2023 | |
| Journey Medical Corporation | $89.92 | 2022-2025 | |
| Allergan, INC. | $66.95 | 2020 | |
| Organon LLC | $44.19 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $37.28 | 2024-2025 | Nemluvio |
| Krystal Biotech INC | $24.07 | 2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $21.39 | 2024 | Ycanth |
| Genentech USA, INC. | $21.16 | 2019 | |
| Almirall LLC | $19.23 | 2024 | Klisyri |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.